SHENZHEN, China, Aug. 28, 2024 /CNW/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move not only marks UTime's in-depth expansion in the global vaccine market, but also provides strong support for the registration of the relevant vaccine through the U.S. Food and Drug Administration (the "FDA").
Read more at newswire.caUTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines
Newswire.ca - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Apple%20products%20arranged%20on%20desk%20by%20tashka2000%20via%20iStock.jpg)